Open AccessPharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants
Author(s) -
Aline Barth,
Mohammad Hossain,
Darin Brimhall,
Caroline M. Perry,
Courtney Tiffany,
S.-Q Xu,
Étienne Dumont
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01263-21
Subject(s) - cmax , pharmacokinetics , bioavailability , medicine , confidence interval , pharmacology , adverse effect , placebo , area under the curve , alternative medicine , pathology
Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that may provide a new treatment option for antibiotic-resistant pathogens. Two pharmacokinetic evaluations of oral gepotidacin are presented: a relative bioavailability study that guided formulation development, followed by an adult and adolescent study of the final formulation.